Immunex Corporation

Amgen Inc.

Genentech, Inc.

Stewart D Lyman

M Patricia Beckmann

John Ernest Sims

Peter Robert Baum

Raymond J Paxton

Kirk P Van Ness

Hilary Jean McKenna

Allison P Armstrong

Patricia M Beckmann

Melissa K Carpenter

William C Fanslow, Iii

Allison P Jacob

Hilary J McKenna

Hilary Mckenna

The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

Antibodies that inhibit TSLP activity

Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.

Nucleic acids encoding modified human thymic stromal lymphopoietin

Modified human thymic stromal lymphopoietin

Nucleic acid encoding modified human thymic stromal lymphopoietin

Human TSLP polynucleotides

A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.

Flk-1 binding protein

Antibodies binding to human TSLP Polypeptides

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.

Methods of using flt3-ligand in hematopoietic cell transplantation

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to anti-flt3-L antibodies and enzyme-linked immunosorbent assays comprising such antibodies.

Antibodies against flt3-ligand

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using fit3-L. Flt3-L finds use in treating patients with anemia, AIDS and various cancers.

Ligands for flt3 receptors

FLK-1 binding proteins

Growing community of inventors

Seattle, WA, United States of America

Stewart D Lyman